Mithra Pharmaceuticals
The KBO register records legal situation 050 for Mithra Pharmaceuticals (Register: open bankruptcy); this is today's state according to the register itself, which carries no start date. The 2022 annual accounts show equity of €290.23M and a net result of €-42.54M.
| Equity | €290.23M |
| Net result | €-42.54M |
| Staff (FTE) | 40 |
| Better than sector | 66% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Bankruptcy opened
A bankruptcy procedure is already open, a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 56.5% | 45.8% | |
| Net result | €-42.54M | €-51k | |
| Equity | €290.23M | €262k | |
| Total assets | €513.65M | €2.24M |
Show 14 other metrics
| Fiscal year | 2022 |
|---|---|
| Deposit | volledig |
| Revenue | €23.28M |
| EBITDA | €94k |
| Net profit | €-42.54M |
| Cash flow | €-42.01M |
| Staff costs | €4.02M |
| Income taxes | €2.58M |
| Dividends | - |
| Total assets | €513.65M |
| Equity | €290.23M |
| Debt | €223.15M |
| of which ≤ 1y | €51.48M |
| of which > 1y | €169.54M |
| Working capital | €105.46M |
| Employees (FTE) | 40.0 |
| 2022 | |
|---|---|
| Current ratio | 3.05 |
| Quick ratio | 3.05 |
| Working capital ratio | 20.5% |
| Solvency | 56.5% |
| Debt / equity | 0.77 |
| Long-term debt ratio | 0.58 |
| Interest coverage | 0.01 |
| Gross margin | 99.6% |
| Net margin | -182.8% |
| ROA | -8.3% |
| ROE | -14.7% |
| EBITDA margin | 0.4% |
| Days sales outstanding | 219d |
| Days payable outstanding | 9778d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (26 line items)
| Line item | Code | 2022 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €513.65M |
| Fixed assets | 21/28 | €356.71M |
| Intangible fixed assets | 21 | €1.00M |
| Tangible fixed assets | 22/27 | €1.36M |
| Financial fixed assets | 28 | €354.35M |
| Current assets | 29/58 | €156.94M |
| Amounts receivable within one year | 40/41 | €126.53M |
| Cash & bank | 54/58 | €27.60M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €513.65M |
| Equity | 10/15 | €290.23M |
| Contributions / capital | 10/11 | €453.74M |
| Reserves | 13 | €598k |
| Accumulated profits (losses) | 14 | €-164.10M |
| Provisions & deferred taxes | 16 | €266k |
| Amounts payable | 17/49 | €223.15M |
| Amounts payable after one year | 17 | €169.54M |
| Amounts payable within one year | 42/48 | €51.48M |
| Trade debts payable within one year | 44 | €2.23M |
| Income statement | ||
| Turnover | 70 | €23.28M |
| Operating result | 9901 | €-439k |
| Financial income | 75 | €22.29M |
| Financial charges | 65 | €10.27M |
| Result before taxes | 9903 | €-39.96M |
| Income taxes | 67/77 | €2.58M |
| Net result for the period | 9904 | €-42.54M |
| Result to be appropriated | 9905 | €-42.54M |
-
C2M4E SRLLegal entityDirectorState Gazette act 24058584 (10-04-2024)Current10-04-2024 → present
-
CMM&C SRLLegal entityCo ceoState Gazette act 24058584 (10-04-2024)Current10-04-2024 → present
-
Xavier PaoliCo ceoState Gazette act 24058584 (10-04-2024)Current10-04-2024 → present
-
Bronzet ManagementDaily management delegateState Gazette act 23156925 (07-12-2023)Current07-12-2023 → present
-
Gaudeto SRLLegal entityAdministrateur indépendantState Gazette act 23156926 (07-12-2023)Current07-12-2023 → present
2 events
- 07-12-2023 Appointed· Administrateur indépendant
- 07-12-2023 Resigned· Administrateur indépendant
-
Inge BeernaertDirectorState Gazette act 23156925 (07-12-2023)Current07-12-2023 → present
4 events
- 07-12-2023 Resigned· Director
- 07-12-2023 Appointed· Director
- 07-12-2023 Appointed· Administrateur indépendant
- 07-12-2023 Resigned· Administrateur indépendant
Show 14 more sitting directors
-
Life Science Strategy Consulting SRLLegal entityAdministrateur indépendantState Gazette act 23156926 (07-12-2023)Current07-12-2023 → present
2 events
- 07-12-2023 Appointed· Administrateur indépendant
- 07-12-2023 Resigned· Administrateur indépendant
-
Ribono SRLLegal entityAdministrateur indépendantState Gazette act 23156926 (07-12-2023)Current07-12-2023 → present
2 events
- 07-12-2023 Appointed· Administrateur indépendant
- 07-12-2023 Resigned· Administrateur indépendant
-
David H. SolomonDaily management delegateState Gazette act 23083167 (28-06-2023)Current28-06-2023 → present
-
M. MorettiDirectorState Gazette act 22100967 (23-08-2022)Current23-08-2022 → present
2 events
- 23-08-2022 Appointed· Director
- 23-08-2022 Appointed· Président du conseil d'administration
-
M. Van Den EyndenVice président du conseil d'administrationState Gazette act 22100967 (23-08-2022)Current23-08-2022 → present
-
Alius Modi SRLLegal entityDirectorState Gazette act 23156926 (07-12-2023)Current09-09-2021 → present
2 events
- 07-12-2023 Appointed· Director
- 09-09-2021 Appointed· Administrateur non exécutif
-
Amel TounsiAdministrateur non exécutifState Gazette act 21107869 (09-09-2021)Current09-09-2021 → present
-
An CloetAdministrateur indépendantState Gazette act 21107869 (09-09-2021)Current09-09-2021 → present
-
Eva Consulting SRLLegal entityDirectorState Gazette act 23156926 (07-12-2023)Current09-09-2021 → present
2 events
- 07-12-2023 Appointed· Director
- 09-09-2021 Appointed· Administrateur exécutif
-
Liesbeth WeynantsAdministrateur indépendantState Gazette act 21107869 (09-09-2021)Current09-09-2021 → present
-
Noshaq SALegal entityAdministrateur non exécutifState Gazette act 21107869 (09-09-2021)Current09-09-2021 → present
-
Patricia Van DijckAdministrateur indépendantState Gazette act 21107869 (09-09-2021)Current09-09-2021 → present
-
TicaConsult BVLegal entityAdministrateur indépendantState Gazette act 21107869 (09-09-2021)Current07-05-2021 → present
2 events
- 09-09-2021 Appointed· Administrateur indépendant
- 07-05-2021 Appointed· Administrateur indépendant
-
Van Rompay Management BVLegal entityCeo ad interimState Gazette act 21055287 (07-05-2021)Current07-05-2021 → present
Historic, not recently confirmed (16)
-
YIMA SPRLLegal entityManaging directorState Gazette act 19152809 (25-11-2019)Not recently confirmedlast confirmed in an act from 2019
-
AHOKAdministrateur indépendantState Gazette act 17104970 (19-07-2017)Not recently confirmedlast confirmed in an act from 2017
-
AUBISQUEDirectorState Gazette act 17104970 (19-07-2017)Not recently confirmedlast confirmed in an act from 2017
-
EVA CONSULTINGDirectorState Gazette act 17104970 (19-07-2017)Not recently confirmedlast confirmed in an act from 2017
-
P4MANAGEMENTAdministrateur indépendantState Gazette act 17104970 (19-07-2017)Not recently confirmedlast confirmed in an act from 2017
-
Christiane MalcorpsDirectorState Gazette act 17049355 (06-04-2017)Not recently confirmedlast confirmed in an act from 2017
3 events
- 06-04-2017 Resigned· Director
- 06-04-2017 Appointed· Director
- 16-02-2017 Appointed· Director
-
P4MANAGEMENT BVBALegal entityDirectorState Gazette act 17049355 (06-04-2017)Not recently confirmedlast confirmed in an act from 2017
-
Ahok BVBALegal entityDirectorState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
3 events
- 26-09-2016 Appointed· Director
- 26-09-2016 Appointed· Membre du comité d'audit
- 26-09-2016 Appointed· Président du comité d'audit
-
Alychlo SALegal entityMembre du comité de nomination et de rémunérationState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
-
Aubisque BVBALegal entityDirectorState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
-
Eva Consulting SPRLLegal entityDirectorState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
-
Jacques PlatieauMembre du comité de nomination et de rémunérationState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
2 events
- 23-07-2019 Resigned· Director
- 26-09-2016 Appointed· Membre du comité de nomination et de rémunération
-
Meusinvest SALegal entityMembre du comité d'auditState Gazette act 16132601 (26-09-2016)Not recently confirmedlast confirmed in an act from 2016
-
ARDENTIA INVESTDirectorState Gazette act 11106784 (13-07-2011)Not recently confirmedlast confirmed in an act from 2011
-
MAJOCEPIDirectorState Gazette act 11106784 (13-07-2011)Not recently confirmedlast confirmed in an act from 2011
-
YIMAManaging directorState Gazette act 11106784 (13-07-2011)Not recently confirmedlast confirmed in an act from 2011
2 events
- 13-07-2011 Resigned· Managing director
- 13-07-2011 Appointed· Managing director
Permanent representatives (3)
-
Christophe PelzerRepresentant permanent commissaireState Gazette act 23003396 (06-01-2023)Permanent representative06-01-2023 → present
-
Jacques PlatieauReprésentant permanentState Gazette act 19099210 (23-07-2019)Permanent representative23-07-2019 → present
-
Cédric AntonelliRepresentant permanent commissaireState Gazette act 23003396 (06-01-2023)Permanent representative- → 06-01-2023
Former directors (22)
-
Castors Development SALegal entityAdministrateur indépendantState Gazette act 23156926 (07-12-2023)Former23-07-2019 → 10-04-2024
4 events
- 10-04-2024 Resigned· Director
- 07-12-2023 Appointed· Administrateur indépendant
- 07-05-2021 Resigned· Administrateur indépendant, président du comité de nomination et rémunération
- 23-07-2019 Appointed· Director
-
CEODirecteur généralState Gazette act 24058584 (10-04-2024)Former- → 10-04-2024
-
David Horn SolomonDaily management delegateState Gazette act 23156925 (07-12-2023)Former- → 07-12-2023
-
Leon Van RompayDaily management delegateState Gazette act 23083167 (28-06-2023)Former- → 28-06-2023
-
Sunathim BVLegal entityAdministrateur indépendantState Gazette act 21107869 (09-09-2021)Former07-05-2021 → 23-08-2022
3 events
- 23-08-2022 Resigned· Director
- 09-09-2021 Appointed· Administrateur indépendant
- 07-05-2021 Appointed· Administrateur indépendant
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO Réviseurs d'entreprises SCRLCurrent Commissaire |
- | 09-09-2021 → present |
Show 1 earlier auditors
| BDO Réviseurs d'entreprises Commissaire succeeded by BDO Réviseurs d'entreprises SCRL in 2021 |
- | 29-08-2018 → 09-09-2021 |
| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | YVES GODFROID RUE DES AUGUSTINS 32,
4000 LIEGE 1 |
10-06-2024 → present | Belgian State Gazette |
| Curator | FRANCOIS MINON RUE DES AUGUSTINS 32, 4000 LIEGE 1- francois.minon@henry-
mersch.be |
10-06-2024 → present | Belgian State Gazette |
| NACE primary | Vervaardiging van geneesmiddelen(21201) |
| Legal form | Public limited company(014) |
| Incorporation | 13-07-1999 |
| Status | Active |
| Postal code | 4000 |
| First BS signal | 14-06-2024 |
| Latest BS signal | 03-07-2024 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62810C0909/00G000 | Wallonia | 126 m² | 1 · 43 m² | 16.9 m · 5 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
The full chronology lists every recorded event with its date, the competent court and the appointed liquidator or administrator. It answers at which stage the proceedings stand and whether they are still running.
We hold 1 further earlier event in this file, covering 10-06-2024 to 03-07-2024.
We know of 115 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
10-04-2024 3 directors appointed, 2 resigning
- C2M4E SRL, Bestuurder
- Xavier Paoli, Co ceo
- CMM&C SRL, Co ceo
- Castors Development SA, Bestuurder
- CEO, Directeur général
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Castors Development SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "C2M4E SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "co-CEO",
"person": {
"rrn": null,
"name": "Xavier Paoli",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "co-CEO",
"person": {
"rrn": null,
"name": "CMM\u0026C SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "directeur g\u00E9n\u00E9ral",
"person": {
"rrn": null,
"name": "CEO",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}22-12-2023 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}07-12-2023 2 directors appointed, 2 resigning
- Inge Beernaert, Bestuurder
- Bronzet Management, Dagelijks bestuur
- Inge Beernaert, Bestuurder
- David Horn Solomon, Dagelijks bestuur
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Inge Beernaert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Inge Beernaert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "David Horn Solomon",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Bronzet Management",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}07-12-2023 7 directors appointed, 4 resigning
- Ribono SRL, Administrateur indépendant
- Inge Beernaert, Administrateur indépendant
- Life Science Strategy Consulting SRL, Administrateur indépendant
- Gaudeto SRL, Administrateur indépendant
- Castors Development SA, Administrateur indépendant
- Eva Consulting SRL, Bestuurder
- Alius Modi SRL, Bestuurder
- Life Science Strategy Consulting SRL, Administrateur indépendant
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Ribono SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Inge Beernaert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Life Science Strategy Consulting SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Gaudeto SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Life Science Strategy Consulting SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Gaudeto SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Inge Beernaert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Ribono SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Castors Development SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eva Consulting SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Alius Modi SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}28-11-2023 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}30-08-2023 Capital increase of €20,000,000.00 to €50,212,360.13
- €30.212.360,13 → €50.212.360,13
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 50212360.13,
"delta_eur": 20000000.000000004,
"before_eur": 30212360.13,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}28-06-2023 1 director appointed, 1 resigning
- David H. Solomon, Dagelijks bestuur
- Leon Van Rompay, Dagelijks bestuur
Technical details
{
"events": [
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Leon Van Rompay",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "David H. Solomon",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "MITHRA PHARMACEUTICALS"
}
}27-06-2023 Capital increase of €7,267,813.26 to €42,891,360.13
- €35.623.546,87 → €42.891.360,13
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 42891360.13,
"delta_eur": 7267813.260000005,
"before_eur": 35623546.87,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}27-06-2023 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Geoffrey GAUTHY",
"firm_city": null,
"firm_name": "GAUTHY, JACQUES \u0026 ROLANS \u2013 Soci\u00E9t\u00E9 Notariale",
"office_city": "Herstal",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2023-06-27",
"filing_date": "2023-06-23",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": "raad_van_bestuur",
"act_date": "2023-06-21",
"unanimous": true
},
"conversion": null,
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0466.526.646",
"name": "Mithra Pharmaceuticals",
"role": "contributor",
"address": "Rue Saint-Georges 5, 4000 Li\u00E8ge",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"7:179",
"7:181",
"7:186",
"7:197",
"7:198"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": false,
"patrimony_description": "Apport en nature de cr\u00E9ances dues par la soci\u00E9t\u00E9, issues des Conventions Modifi\u00E9es (pr\u00EAts convertibles seniors et accord de conversion), en vue d\u0027une augmentation de capital et d\u0027\u00E9mission de nouvelles actions.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"detected_kind_raw": "capital_shares",
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "GAUTHY, JACQUES \u0026 ROLANS \u2013 Soci\u00E9t\u00E9 Notariale",
"person_name": null,
"org_rep_person_name": "Geoffrey GAUTHY"
},
"summary_narrative": "Le conseil d\u0027administration de Mithra Pharmaceuticals a d\u00E9cid\u00E9 d\u0027augmenter le capital de la soci\u00E9t\u00E9 par apport en nature de cr\u00E9ances dues par celle-ci, issues de conventions de pr\u00EAts convertibles et d\u0027accords de conversion conclus avec des fonds g\u00E9r\u00E9s par Highbridge Capital Management et Whitebox Advisors. L\u0027op\u00E9ration, soumise \u00E0 des conditions suspensives, pr\u00E9voit l\u0027\u00E9mission de nouvelles actions en contrepartie de ces apports, dont le nombre et le prix d\u0027\u00E9mission seront d\u00E9termin\u00E9s ult\u00E9rieurement. Le conseil a \u00E9galement nomm\u00E9 un comit\u00E9 charg\u00E9 de mettre en \u0153uvre l\u0027op\u00E9ration, y compris la pr\u00E9para",
"co_filed_documents": [
"exp\u00E9dition de l\u2019acte comprenant les procurations, le rapport du CA et le rapport du commissaire.",
"la coordination des statuts."
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}31-05-2023 Capital increase of €2,000,000 to €42,824,254
- €40.824.254 → €42.824.254
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 42824254.0,
"delta_eur": 2000000.0,
"before_eur": 40824254.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}30-05-2023 Capital increase to €2,500,000.80
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 2500000.8,
"delta_eur": null,
"before_eur": null,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}16-05-2023 Capital increase of €208,947.61 to €41,992,326.28
- €41.783.378,67 → €41.992.326,28
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 41992326.28,
"delta_eur": 208947.6099999994,
"before_eur": 41783378.67,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}15-03-2023 Capital increase of €1,854,570.72 to €41,783,378.35
- €39.928.807,63 → €41.783.378,35
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 41783378.35,
"delta_eur": 1854570.7199999988,
"before_eur": 39928807.63,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}16-02-2023 Capital increase of €721,159.80 to €36,960,159.80
- €36.239.000 → €36.960.159,80
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 36960159.8,
"delta_eur": 721159.799999997,
"before_eur": 36239000,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}06-01-2023 1 director appointed, 1 resigning
- Christophe Pelzer, Representant permanent commissaire
- Cédric Antonelli, Representant permanent commissaire
Technical details
{
"events": [
{
"kind": "director_in",
"role": "representant permanent commissaire",
"person": {
"rrn": null,
"name": "Christophe Pelzer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representant permanent commissaire",
"person": {
"rrn": null,
"name": "C\u00E9dric Antonelli",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "MITHRA PHARMACEUTICALS SA"
}
}06-01-2023 Capital increase of €8,227,972.15 to €41,227,972.15
- €33.000.000 → €41.227.972,15
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 41227972.15,
"delta_eur": 8227972.1499999985,
"before_eur": 33000000,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}28-12-2022 Capital increase of €2,629,403.05 to €41,036,161.95
- €38.406.758,90 → €41.036.161,95
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 41036161.95,
"delta_eur": 2629403.0500000045,
"before_eur": 38406758.9,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}09-12-2022 Capital increase of €1,235,314.04 to €40,535,314.04
- €39.300.000 → €40.535.314,04
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 40535314.04,
"delta_eur": 1235314.039999999,
"before_eur": 39300000,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}06-12-2022 Capital increase of €302,517.23 to €40,302,517.22
- €39.999.999,99 → €40.302.517,22
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 40302517.22,
"delta_eur": 302517.2299999967,
"before_eur": 39999999.99,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}02-12-2022 Capital increase of €223,994.09 to €39,438,268.05
- €39.214.273,96 → €39.438.268,05
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39438268.05,
"delta_eur": 223994.08999999613,
"before_eur": 39214273.96,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}02-12-2022 Capital increase of €2,147,357.71 to €40,092,606.58
- €37.945.248,87 → €40.092.606,58
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 40092606.58,
"delta_eur": 2147357.710000001,
"before_eur": 37945248.87,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}24-11-2022 Capital increase of €192,121.03 to €39,630,388.66
- €39.438.267,63 → €39.630.388,66
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39630388.66,
"delta_eur": 192121.02999999374,
"before_eur": 39438267.63,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}08-11-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}26-10-2022 Capital increase to €39,187,430.09
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39187430.09,
"delta_eur": null,
"before_eur": null,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}20-10-2022 Capital increase of €125,581.53 to €39,187,430.09
- €39.061.848,56 → €39.187.430,09
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39187430.09,
"delta_eur": 125581.53000000119,
"before_eur": 39061848.56,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}04-10-2022 Capital increase of €384,544.32 to €39,061,849.32
- €38.677.305 → €39.061.849,32
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39061849.32,
"delta_eur": 384544.3200000003,
"before_eur": 38677305.0,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}28-09-2022 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Olivier JACQUES",
"firm_city": null,
"firm_name": "GAUTHY \u0026 JACQUES \u2013 Notaires Associ\u00E9s",
"office_city": "Herstal",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-09-28",
"filing_date": "2022-09-26",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2022-09-22",
"unanimous": null
},
"conversion": null,
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [],
"exchange_ratio": null,
"legal_articles": [
"7:180",
"7:191",
"7:193"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": false,
"patrimony_description": "La prolongation de la dur\u00E9e des droits de souscription (Droits de Souscription de LDA et Droits de Souscription pour Pr\u00EAt d\u0027Action de Cat\u00E9gories A, B et C) n\u0027implique pas de transfert de patrimoine. Il s\u0027agit d\u0027une simple extension de la p\u00E9riode d\u0027exercice de ces droits, sans modification des conditions initiales.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Olivier JACQUES",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des actionnaires de Mithra Pharmaceuticals, r\u00E9unie le 22 septembre 2022, a approuv\u00E9 la prolongation de deux ans de la dur\u00E9e des droits de souscription \u00E9mis en 2020, tant pour LDA Capital Limited que pour les actionnaires concern\u00E9s par les cat\u00E9gories A, B et C du pr\u00EAt d\u0027actions. Ces d\u00E9cisions n\u0027entra\u00EEnent aucune modification des conditions initiales des droits, mais seulement une extension de leur p\u00E9riode d\u0027exercice, de trois \u00E0 cinq ans.",
"co_filed_documents": [
"exp\u00E9dition de l\u2019assembl\u00E9e comprenant le PV de carence, les rapports de l\u2019organe d\u2019administration, le rapport du commissaire, la liste de pr\u00E9sence, les avis de participation et les attestation de d\u00E9ten tion",
"la coordination des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "statutes"
}28-09-2022 Capital increase of €329,957.66 to €39,007,694.42
- €38.677.736,76 → €39.007.694,42
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 39007694.42,
"delta_eur": 329957.6600000039,
"before_eur": 38677736.76,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}28-09-2022 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Olivier JACQUES",
"firm_city": null,
"firm_name": "GAUTHY \u0026 JACQUES \u2013 Notaires Associ\u00E9s",
"office_city": "Herstal",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-09-28",
"filing_date": "2022-09-26",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": "bijzondere_algemene_vergadering",
"act_date": "2022-09-22",
"unanimous": null
},
"conversion": null,
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0466.526.646",
"name": "Mithra Pharmaceuticals",
"role": "other",
"address": "Rue Saint-Georges 5, 4000 Li\u00E8ge",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Selva Luxembourg S.\u00E0.r.l.",
"role": "other",
"address": null,
"is_foreign": true,
"legal_form": "S.\u00E0.r.l.",
"is_new_company": false,
"jurisdiction_country": "LU"
}
],
"exchange_ratio": null,
"legal_articles": [
"7:151"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Aucun transfert de patrimoine n\u0027est effectu\u00E9. L\u0027acte concerne la nomination d\u0027un administrateur et l\u0027approbation de clauses contractuelles li\u00E9es \u00E0 un changement de contr\u00F4le.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "GAUTHY \u0026 JACQUES \u2013 Notaires Associ\u00E9s",
"person_name": null,
"org_rep_person_name": "Olivier JACQUES"
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale sp\u00E9ciale des actionnaires de Mithra Pharmaceuticals, r\u00E9unie le 22 septembre 2022, a nomm\u00E9 Selva Luxembourg S.\u00E0.r.l. en tant qu\u0027administrateur pour une dur\u00E9e s\u0027\u00E9tendant jusqu\u0027\u00E0 la cl\u00F4ture de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2023. Elle a \u00E9galement approuv\u00E9 et ratifi\u00E9 les clauses des conventions li\u00E9es \u00E0 un changement de contr\u00F4le, conform\u00E9ment \u00E0 l\u0027article 7:151 du Code des soci\u00E9t\u00E9s et des associations, et a attribu\u00E9 une procuration sp\u00E9ciale aux administrateurs et aux dirigeants de la soci\u00E9t\u00E9 pour les formalit\u00E9s de publication.",
"co_filed_documents": [
"exp\u00E9dition de l\u2019assembl\u00E9e comprenant la liste de pr\u00E9sence, les avis de participation et les attestations de d\u00E9tention",
"proc\u00E8s-verbal de l\u2019assembl\u00E9e g\u00E9n\u00E9rale ordinaire du 20 mai 2021",
"proc\u00E8s-verbal de l\u2019assembl\u00E9e g\u00E9n\u00E9rale ordinaire du 19 mai 2022",
"la coordination des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "director_changes"
}16-09-2022 Capital increase of €71,504.06 to €38,774,037.39
- €38.702.533,33 → €38.774.037,39
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 38774037.39,
"delta_eur": 71504.06000000238,
"before_eur": 38702533.33,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0466.526.646",
"name_full": "Mithra Pharmaceuticals"
}
}| Legal nameFR | Mithra Pharmaceuticals |